Translational Drug Development (TD2)
Brittany Gilpin is a Nonclinical Project Manager at Translational Drug Development (TD2) since April 2022, where responsibilities include client collaboration, study protocol development, project timeline management, and quality control of data and reports. Prior experience at Labcorp Drug Development includes roles as Supervisor of Anatomical Pathology and Lead Anatomical Pathology Technician, focusing on adherence to study protocols and regulatory compliance. Brittany began a career as a Veterinary Technician at Animal Medical Center, providing client education and assistance in clinical procedures. Academic qualifications include a Master’s degree in Clinical Research/Regulatory Affairs from The Ohio State University and dual Bachelor of Science degrees in Kinesiology and Exercise Science and Biology from Ball State University.
This person is not in any offices
Translational Drug Development (TD2)
Translational Drug Development (TD2) is an oncology-focused Contract Research Organization (CRO) that supports improved and accelerated development of medicines for life-threatening diseases. We help companies move their drugs through the critical stages of preclinical, regulatory and clinical trial processes. Our scientific depth, proactive problem solving, and strategic direction and advice increase the likelihood of positive outcomes that bring hope and a better quality of life to cancer patients and their families. TD2 was born from the Translational Genomics Research Institute (TGen) as a nonprofit in 2003. TGen’s deep scientific expertise and approach to interrogating the “omic” drivers of disease is at the heart of TD2’s heritage and has become the foundation upon which TD2 creates unique clinical strategies for its clients.